Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), has received two positive opinions recommending approval for an extension of the indication for PREVENARTM (Pneumococcal Saccharide Conjugated Vaccine, Adsorbed) to the European market by the Committee for Medicinal Products for Human Use (CHMP). The opinions recommend extending the indications of PREVENAR to include active immunization against pneumonia and acute otitis media (middle ear infection) caused by vaccine serotypes. PREVENAR is